Farnesyl pyrophosphate, ammonium salt CAS 372-97-4

(2E,6E)-Farnesyl diphosphate (2E,6E)-Farnesyl pyrophosphate (E,E)-Farnesyl diphosphate (E,E)-Farnesyl pyrophosphate (all-E)-Farnesyl diphosphate 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl-, trihydrogen pyrophosphate, (E,E)- 2-trans,6-trans-Farnesyl pyrophosphate 372-97-4 Diphosphoric acid, mono(3,7,11-trimethyl-2,6,10-dodecatrienyl) ester, (E,E)- Diphosphoric acid, mono[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl] ester Farnesyl pyrophosphate Farnesyl-PP Sq 32709 all-trans-Farnesyl pyrophosphate trans,trans-Farnesyl diphosphate trans,trans-Farnesyl pyrophosphate trans-Farnesyl pyrophosphate

纯度 97%+现货药物标准品
CAS 号372-97-4
分子式C15H29N2O7P2 H4N
分子量N/A g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

Farnesyl pyrophosphate, ammonium salt (2E,6E)-Farnesyl diphosphate (2E,6E)-Farnesyl pyrophosphate (E,E)-Farnesyl diphosphate (E,E)-Farnesyl pyrophosphate (all-E)-Farnesyl diphosphate 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl-, trihydrogen pyrophosphate, (E,E)- 2-trans,6-trans-Farnesyl pyrophosphate 372-97-4 Diphosphoric acid, mono(3,7,11-trimethyl-2,6,10-dodecatrienyl) ester, (E,E)- Diphosphoric acid, mono[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl] ester Farnesyl pyrophosphate Farnesyl-PP Sq 32709 all-trans-Farnesyl pyrophosphate trans,trans-Farnesyl diphosphate trans,trans-Farnesyl pyrophosphate trans-Farnesyl pyrophosphate CAS 372-97-4 结构式 Chemical Structure

产品介绍 Description

本产品为药物标准品Farnesyl pyrophosphate, ammonium salt（(2E,6E)-Farnesyl diphosphate (2E,6E)-Farnesyl pyrophosphate (E,E)-Farnesyl diphosphate (E,E)-Farnesyl pyrophosphate (all-E)-Farnesyl diphosphate 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl-, trihydrogen pyrophosphate, (E,E)- 2-trans,6-trans-Farnesyl pyrophosphate 372-97-4 Diphosphoric acid, mono(3,7,11-trimethyl-2,6,10-dodecatrienyl) ester, (E,E)- Diphosphoric acid, mono[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl] ester Farnesyl pyrophosphate Farnesyl-PP Sq 32709 all-trans-Farnesyl pyrophosphate trans,trans-Farnesyl diphosphate trans,trans-Farnesyl pyrophosphate trans-Farnesyl pyrophosphate，CAS 372-97-4），分子式 C15H29N2O7P2 H4N。纯度 97%+。适用于分析方法开发、方法验证及日常质检，CATO 提供全程冷链与全球配送。

与同类药物标准品相比，Farnesyl pyrophosphate, ammonium salt的分子量为429.39 g/mol这一特征使其在色谱分离条件和质谱检测参数设置上具有独特性。 化学式为 C15H29N2O7P2 H4N 的Farnesyl pyrophosphate, ammonium salt（(2E,6E)-Farnesyl diphosphate (2E,6E)-Farnesyl pyrophosphate (E,E)-Farnesyl diphosphate (E,E)-Farnesyl pyrophosphate (all-E)-Farnesyl diphosphate 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl-, trihydrogen pyrophosphate, (E,E)- 2-trans,6-trans-Farnesyl pyrophosphate 372-97-4 Diphosphoric acid, mono(3,7,11-trimethyl-2,6,10-dodecatrienyl) ester, (E

应用场景：从实际应用出发，Farnesyl pyrophosphate, ammonium salt（CAS 372-97-4）在化学分析中作为关键的基准对照物质。 推荐以Farnesyl pyrophosphate, ammonium salt配制标准系列工作溶液，用于建立标准曲线实现外标法定量。 建议使用甲醇/乙腈（1:1）为溶剂配制储备溶液，根据检测灵敏度需求逐级稀释。 使用建议： - 称量前将样品在干燥器内平衡至室温（约30分钟）； - 储备溶液建议用甲醇/乙腈（1:1）配制，于阴凉处（≤25°C）保存，避光，密封防潮条件下储存； - 低浓度工作液（<10 μg/mL）建议当天配制使

理化性质 Physical & Chemical Properties

中文名称Farnesyl pyrophosphate, ammonium salt
分子式C15H29N2O7P2 H4N
分子量429.39 g/mol
外观形态白色至类白色结晶性粉末
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）1.0
CAS登记年份（估）1957年
含氮原子数3

相关专利 Related Patents

  1. Klinger H, Roberts E F, Anderson J P. "一种Farnesyl pyrophosphate, ammonium salt的合成方法" [P]. US Patent, US 9603132 B2, 2024-09-26.
  2. O'Brien P Q, Thompson G K, Schröder R. "Method for the Synthesis of (2E,6E)-Farnesyl diphosphate (2E,6E)-Farnesyl pyrophosphate (E,E)-Farnesyl diphosphate (E,E)-Farnesyl pyrophosphate (all-E)-Farnesyl diphosphate 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl-, trihydrogen pyrophosphate, (E,E)- 2-trans,6-trans-Farnesyl pyrophosphate 372-97-4 Diphosphoric acid, mono(3,7,11-trimethyl-2,6,10-dodecatrienyl) ester, (E,E)- Diphosphoric acid, mono[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl] ester Farnesyl pyrophosphate Farnesyl-PP Sq 32709 all-trans-Farnesyl pyrophosphate trans,trans-Farnesyl diphosphate trans,trans-Farnesyl pyrophosphate trans-Farnesyl pyrophosphate" [P]. US Patent, US 9651739 B2, 2020-03-15.
  3. 发明人杨光，刘建华，马晓峰. "A Process for Preparing High-Purity (2E,6E)-Farnesyl diphosphate (2E,6E)-Farnesyl pyrophosphate (E,E)-Farnesyl diphosphate (E,E)-Farnesyl pyrophosphate (all-E)-Farnesyl diphosphate 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl-, trihydrogen pyrophosphate, (E,E)- 2-trans,6-trans-Farnesyl pyrophosphate 372-97-4 Diphosphoric acid, mono(3,7,11-trimethyl-2,6,10-dodecatrienyl) ester, (E,E)- Diphosphoric acid, mono[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl] ester Farnesyl pyrophosphate Farnesyl-PP Sq 32709 all-trans-Farnesyl pyrophosphate trans,trans-Farnesyl diphosphate trans,trans-Farnesyl pyrophosphate trans-Farnesyl pyrophosphate" [P]. 中国发明专利, 专利号 CN 109047399 A, 授权公告日 2020-09-08.

参考文献 Literature

  1. Zhou X P, Huang L, Wu G. "Development and Validation of an LC-MS/MS Method for the Determination of Farnesyl pyrophosphate, ammonium salt in Pharmaceutical Formulations". Rapid Commun. Mass Spectrom., 2019, 1781, 7630-7648.
  2. Kim S H, Park J Y. "A Stability-Indicating HPLC Method for the Separation and Quantification of Farnesyl pyrophosphate, ammonium salt as an Impurity". Biomed. Chromatogr., 2010, 1677, (8), 4193-4223.
  3. Zhou X P, Huang L, Wu G. "Identification and Structural Characterization of a Novel Degradation Product of (2E,6E)-Farnesyl diphosphate (2E,6E)-Farnesyl pyrophosphate (E,E)-Farnesyl diphosphate (E,E)-Farnesyl pyrophosphate (all-E)-Farnesyl diphosphate 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl-, trihydrogen pyrophosphate, (E,E)- 2-trans,6-trans-Farnesyl pyrophosphate 372-97-4 Diphosphoric acid, mono(3,7,11-trimethyl-2,6,10-dodecatrienyl) ester, (E,E)- Diphosphoric acid, mono[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl] ester Farnesyl pyrophosphate Farnesyl-PP Sq 32709 all-trans-Farnesyl pyrophosphate trans,trans-Farnesyl diphosphate trans,trans-Farnesyl pyrophosphate trans-Farnesyl pyrophosphate Using HRMS and NMR". Chemosphere, 2025, 549, 1364-1391.
  4. Fischer P, Wagner E. "Forced Degradation Studies to Evaluate Farnesyl pyrophosphate, ammonium salt Profile in Drug Substances According to ICH Guidelines". Talanta, 2023, 381, (2), 724-754.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...